According to the Reuters 2 report, the U.S. biotechnology company Novavax (Novavax) using patented nanoparticle technology to develop the Wuhan pneumonia (new coronavirus disease, COVID-19) vaccine, confirmed by clinical trials, effective protection rate of 96%, the British variant of the virus strain also has 86% of the effectiveness, the earliest is expected to be approved for use in the United States in May.
According to the report, Novavax CEO Stanley Erck said on the 1st that if the FDA bases its review on the UK trial, which “will be completed in a few weeks,” their COVID-19 vaccine could be approved for use in the US as soon as May.
But Ehrke also said their talks with the FDA are ongoing and that the FDA may request data from the U.S. trial, which could take an additional two months to complete, delaying U.S. authorization until the summer.
According to preliminary data from the U.K. trial released by Novavax in January, the vaccine, which requires two doses, was about 96 percent effective against the original COVID-19 virus and about 86 percent effective against the variant that was first seen in the U.K. and is now widely disseminated.
Novavax’s martial lung vaccine is based on the expression of a recombinant protein in insect cells and its proprietary recombinant protein nanoparticle technology platform, which identifies the antigen of the COVID-19 viral stinger protein and combines its proprietary Matrix-M adjuvant with the vaccine candidate to enhance the immune response. (Matrix-M) adjuvant in combination with the vaccine candidate to enhance the immune response.
The vaccine received a US$384 million (approximately NT$10.7 billion) investment from the Coalition for Epidemic Preparedness Innovations (CEPI) and is therefore also part of the Wuhan Pneumonia Vaccine Global Access Mechanism (COVAX). The vaccine is also a candidate in the Wuhan Pneumonia Vaccine Global Access Mechanism (COVAX).
Ehrke said Novavax’s vaccine is ready for mass production, has tens of millions of doses in stock, and is ready to ship in the U.S. as soon as it is licensed.
He said Novavax has committed to deliver 110 million doses of the vaccine to the U.S. government by the end of the third quarter, and could do so as soon as July.
Recent Comments